Jonathan Miller

Roy Buchanan

Matthew Phipps

Paul Choi

Philip Nadeau

Edward White

Ernesto Rodriguez-Dumont

Kyuwon Choi

Matt Phipps

Phil Nadeau

- Dynavax Technologies is a **commercial-stage vaccine company** focused on developing improved vaccines using its novel adjuvant technology, with its lead asset, HEPLISAV B, generating significant revenue and on a continued growth path.  **[1029142_tx_380479_0]**  The company expects HEPLISAV B revenue to be between **$315 million and $325 million** for the current year.  **[1029142_tx_380479_8]** 
- HEPLISAV B has a strong product profile and commercial execution, particularly in the **retail setting**, where it holds just under **60%** market share as of Q2.  **[1029142_tx_380479_2]**  The retail segment is projected to double in size by **2030**, representing approximately **50%** of the adult hepatitis B market.  **[1029142_tx_380479_2]** 
- The company's pipeline includes Z1018, a shingles vaccine candidate, which demonstrated similar efficacy to Shingrix with **improved tolerability** in its Phase III (Part 1) trial.  **[1029142_tx_380479_4]** **[1029142_tx_380479_5]**  Other pipeline programs include a plague vaccine in collaboration with the DoD, a Lyme disease vaccine, and a pandemic influenza program.  **[1029142_tx_380479_6]** 
- Dynavax maintains a strong financial position, prioritizing maximizing HEPLISAV B's value, advancing pipeline assets to value inflection points, and opportunistically evaluating derisked business development opportunities.  **[1029142_tx_380479_7]**  The company is also willing to return capital to shareholders if appropriate.  **[1029142_tx_380479_7]**

Dynavax Technologies Discusses HEPLISAV B Growth and Pipeline Advancement

DYNAVAX TECHNOLOGIES (DVAX)